BioSpace News Archive

Medline today announced that it has been awarded a five-year cooperative agreement with OMNIA Partners, one of the nation’s largest purchasing organizations for public and private sector procurement. In effect as of November 1, 2021, the publicly solicited contract is available nationwide.

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, announced the submission of public comments to the Food and Drug Administration concerning its proposed rule to create a new regulatory category of over the counter hearing aids.

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that on January 16, 2022, the company granted non-statutory stock options to purchase an aggregate of 80,675 shares of the company’s common stock to 80 newly hired employees, including 77 newly hired employees based in India.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2).

Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business Update call on January 6, 2022, it will release its financial results for the fourth quarter and fiscal year ended December 31, 2021, after the market closes on Wednesday, March 2, 2022, at approximately 4:00 p.m. Eastern Time.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 435,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the appointment of Michael Beaulieu as Vice President, Investor Relations and Corporate Communications.

TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and treatment through its complementary therapeutics platform, TellRx, announces publication of data from the scientific founders that provide insights into mechanisms of PI3K/mTOR signaling in preclinical models of prostate cancer.

NuGen Medical Devices Inc. announces that it has agreed to settle an aggregate of $500,000 of indebtedness owed to an arm’s length creditor with respect to royalty payments due to the Creditor through the issuance of an aggregate of 1,644,736 common shares of the Company at a price of $0.304 per Common Share.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions, declared a quarterly cash dividend of $0.38 per share.